Literature DB >> 15142887

DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.

Mark R Velangi1, Elizabeth C Matheson, Gareth J Morgan, Graham H Jackson, Penelope R Taylor, Andrew G Hall, Julie A E Irving.   

Abstract

Genetic instability is a prominent feature in multiple myeloma and progression of this disease from monoclonal gammopathy of uncertain significance (MGUS) and smouldering myeloma (SMM) is associated with increasing molecular and chromosomal abnormalities. The DNA mismatch repair (MMR) pathway is a post-replicational DNA repair system that maintains genetic stability by repairing mismatched bases and insertion/deletion loops mistakenly incorporated during DNA replication. Deficiencies in proteins pivotal to this pathway result in a higher mutation rate, particularly at regions of microsatellite DNA. We have investigated the proficiency of the MMR pathway in clinical samples and myeloma cell lines. Microsatellite analysis showed instability at one or more of nine loci examined in 15 from 92 patients: 7.7% of MGUS/SMM, 20.7% of MM/plasma cell leukaemia (PCL) and 12.5% of relapsed MM/PCL. An in vitro heteroduplex G/T repair assay found reduced repair in two cell lines, JIM1 and JIM3, and in two of four PCL cases and was associated with aberrant expression of at least one mismatch repair protein. Thus we show that MMR defects are found in plasma cell dyscrasias and the increased frequency during more active stages of the disease suggests a contributory role in disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142887     DOI: 10.1093/carcin/bgh187

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

1.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

2.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

3.  Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.

Authors:  Israel Zighelboim; Sheri Babb; Feng Gao; Matthew A Powell; David G Mutch; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2007-03-01       Impact factor: 5.482

4.  Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.

Authors:  H Dean Hosgood; Dalsu Baris; Yawei Zhang; Sonja I Berndt; Idan Menashe; Lindsay M Morton; Kyoung-Mu Lee; Meredith Yeager; Shelia H Zahm; Stephen Chanock; Tongzhang Zheng; Qing Lan
Journal:  Leuk Res       Date:  2009-04-11       Impact factor: 3.156

Review 5.  Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Authors:  Elisa Taiana; Maria Eugenia Gallo Cantafio; Vanessa Katia Favasuli; Cecilia Bandini; Giuseppe Viglietto; Roberto Piva; Antonino Neri; Nicola Amodio
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

Review 6.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

Review 7.  DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.

Authors:  Takayuki Saitoh; Tsukasa Oda
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

8.  THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors.

Authors:  Pavithra Shyamsunder; Shree Pooja Sridharan; Vikas Madan; Pushkar Dakle; Cao Zeya; Deepika Kanojia; Wee-Joo Chng; S Tiong Ong; H Phillip Koeffler
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

9.  Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Authors:  M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

10.  Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.

Authors:  Rebecca J Leeman-Neill; Craig R Soderquist; Francesca Montanari; Patricia Raciti; David Park; Dejan Radeski; Mahesh M Mansukhani; Vundavalli V Murty; Susan Hsiao; Bachir Alobeid; Govind Bhagat
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.